Literature DB >> 24865969

Human marrow stromal cells downsize the stem cell fraction of lung cancers by fibroblast growth factor 10.

Masahiko Kanehira1, Toshiaki Kikuchi2, Arif Santoso1, Naoki Tode1, Taizou Hirano1, Shinya Ohkouchi3, Tsutomu Tamada3, Hisatoshi Sugiura3, Hideo Harigae4, Masakazu Ichinose5.   

Abstract

The functional interplay between cancer cells and marrow stromal cells (MSCs) has attracted a great deal of interest due to the MSC tropism for tumors but remains to be fully elucidated. In this study, we investigated human MSC-secreted paracrine factors that appear to have critical functions in cancer stem cell subpopulations. We show that MSC-conditioned medium reduced the cancer stem cell-enriched subpopulation, which was detected as a side population and quiescent (G0) cell cycle fraction in human lung cancer cells by virtue of fibroblast growth factor 10 (FGF10). This reduction of the stem cell-enriched fraction was also observed in lung cancer cells supplemented with recombinant human FGF10 protein. Moreover, supplementary FGF10 attenuated the expression of stemness genes encoding transcription factors, such as OCT3/4 and SOX2, and crippled the self-renewal capacity of lung cancer cells, as evidenced by the impaired formation of floating spheres in the suspension culture. We finally confirmed the therapeutic potential of the FGF10 treatment, which rendered lung cancer cells prone to a chemotherapeutic agent, probably due to the reduced cancer stem cell subpopulation. Collectively, these results add further clarification to the molecular mechanisms underlying MSC-mediated cancer cell kinetics, facilitating the development of future therapies.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24865969      PMCID: PMC4135576          DOI: 10.1128/MCB.00871-13

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

Review 1.  Genetic control of branching morphogenesis.

Authors:  R J Metzger; M A Krasnow
Journal:  Science       Date:  1999-06-04       Impact factor: 47.728

2.  Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.

Authors:  Christine M Fillmore; Piyush B Gupta; Jenny A Rudnick; Silvia Caballero; Patricia J Keller; Eric S Lander; Charlotte Kuperwasser
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

3.  FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo.

Authors:  J C Clark; J W Tichelaar; S E Wert; N Itoh; A K Perl; M T Stahlman; J A Whitsett
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-04       Impact factor: 5.464

Review 4.  Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization.

Authors:  Virginia Tirino; Vincenzo Desiderio; Francesca Paino; Alfredo De Rosa; Federica Papaccio; Marcella La Noce; Luigi Laino; Francesco De Francesco; Gianpaolo Papaccio
Journal:  FASEB J       Date:  2012-09-28       Impact factor: 5.191

5.  Cancer stem cells and chemosensitivity.

Authors:  Marcello Maugeri-Saccà; Paolo Vigneri; Ruggero De Maria
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

Review 6.  Exploring mechanisms of FGF signalling through the lens of structural biology.

Authors:  Regina Goetz; Moosa Mohammadi
Journal:  Nat Rev Mol Cell Biol       Date:  2013-02-13       Impact factor: 94.444

7.  OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice.

Authors:  Jamal Zaini; Sita Andarini; Minoru Tahara; Yasuo Saijo; Naoto Ishii; Kazuyoshi Kawakami; Masaru Taniguchi; Kazuo Sugamura; Toshihiro Nukiwa; Toshiaki Kikuchi
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

8.  Fgf10 is essential for limb and lung formation.

Authors:  K Sekine; H Ohuchi; M Fujiwara; M Yamasaki; T Yoshizawa; T Sato; N Yagishita; D Matsui; Y Koga; N Itoh; S Kato
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

Review 9.  Worldwide overview of the current status of lung cancer diagnosis and treatment.

Authors:  Paul A Bunn
Journal:  Arch Pathol Lab Med       Date:  2012-12       Impact factor: 5.534

Review 10.  The evolving concept of cancer and metastasis stem cells.

Authors:  Irène Baccelli; Andreas Trumpp
Journal:  J Cell Biol       Date:  2012-08-06       Impact factor: 10.539

View more
  5 in total

1.  Human mesenchymal stem cells enhance the systemic effects of radiotherapy.

Authors:  Virgínea de Araújo Farias; Francisco O'Valle; Borja Alonso Lerma; Carmen Ruiz de Almodóvar; Jesús J López-Peñalver; Ana Nieto; Ana Santos; Beatriz Irene Fernández; Ana Guerra-Librero; María Carmen Ruiz-Ruiz; Damián Guirado; Thomas Schmidt; Francisco Javier Oliver; José Mariano Ruiz de Almodóvar
Journal:  Oncotarget       Date:  2015-10-13

2.  Exosomal miR-150 partially attenuated acute lung injury by mediating microvascular endothelial cells and MAPK pathway.

Authors:  Jiaxin Xu; Dan Xu; Zhizhong Yu; Zhaohui Fu; Zheng Lv; Lei Meng; Xin Zhao
Journal:  Biosci Rep       Date:  2022-01-28       Impact factor: 3.840

3.  Multi-cycle chemotherapy with the glycolipid-like polymeric micelles evade cancer stem cell enrichment in breast cancer therapy.

Authors:  Tingting Meng; Jingwen Liu; Lijuan Wen; Ming Yuan; Bolin Cheng; Yingwen Hu; Yun Zhu; Xuan Liu; Hong Yuan; Fuqiang Hu
Journal:  Oncotarget       Date:  2016-11-08

4.  Fibroblast growth factor 10 alleviates particulate matter-induced lung injury by inhibiting the HMGB1-TLR4 pathway.

Authors:  Lingjing Liu; Chenjian Song; Jingli Li; Qiang Wang; Mingyang Zhu; Yiran Hu; Junjie Chen; Chaolei Chen; Jin-San Zhang; Nian Dong; Chengshui Chen
Journal:  Aging (Albany NY)       Date:  2020-01-20       Impact factor: 5.682

5.  Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer.

Authors:  Ragima Nadesh; Krishnakumar N Menon; Lalitha Biswas; Ullas Mony; K Subramania Iyer; Sundeep Vijayaraghavan; Ajit Nambiar; Shantikumar Nair
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.